TW200637847A - Substituted triazole derivatives as oxytocin antagonists - Google Patents

Substituted triazole derivatives as oxytocin antagonists

Info

Publication number
TW200637847A
TW200637847A TW095102071A TW95102071A TW200637847A TW 200637847 A TW200637847 A TW 200637847A TW 095102071 A TW095102071 A TW 095102071A TW 95102071 A TW95102071 A TW 95102071A TW 200637847 A TW200637847 A TW 200637847A
Authority
TW
Taiwan
Prior art keywords
triazole derivatives
substituted triazole
oxytocin antagonists
oxytocin
antagonists
Prior art date
Application number
TW095102071A
Other languages
English (en)
Inventor
Alan Daniel Brown
Andrew Antony Calabrese
David Ellis
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TW200637847A publication Critical patent/TW200637847A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095102071A 2005-01-20 2006-01-19 Substituted triazole derivatives as oxytocin antagonists TW200637847A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0501190.3A GB0501190D0 (en) 2005-01-20 2005-01-20 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
TW200637847A true TW200637847A (en) 2006-11-01

Family

ID=34259404

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095102071A TW200637847A (en) 2005-01-20 2006-01-19 Substituted triazole derivatives as oxytocin antagonists

Country Status (32)

Country Link
US (5) US7557131B2 (zh)
EP (1) EP1841758B1 (zh)
JP (1) JP4124805B1 (zh)
KR (1) KR100936854B1 (zh)
CN (1) CN101107243B (zh)
AP (1) AP2007004047A0 (zh)
AR (1) AR055303A1 (zh)
AT (1) ATE449091T1 (zh)
AU (1) AU2006207300B2 (zh)
BR (1) BRPI0606463A2 (zh)
CA (1) CA2595569C (zh)
CR (1) CR9219A (zh)
DE (1) DE602006010508D1 (zh)
DK (1) DK1841758T3 (zh)
DO (1) DOP2006000014A (zh)
EA (1) EA200701328A1 (zh)
ES (1) ES2334517T3 (zh)
GB (1) GB0501190D0 (zh)
GT (1) GT200600024A (zh)
HK (1) HK1113927A1 (zh)
IL (1) IL184148A (zh)
MA (1) MA29160B1 (zh)
MX (1) MX2007008757A (zh)
NL (1) NL1030961C2 (zh)
NO (1) NO338420B1 (zh)
PA (1) PA8660401A1 (zh)
PE (1) PE20060875A1 (zh)
TN (1) TNSN07275A1 (zh)
TW (1) TW200637847A (zh)
UY (1) UY29339A1 (zh)
WO (1) WO2006077496A1 (zh)
ZA (1) ZA200705718B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06284516A (ja) * 1993-03-31 1994-10-07 Mitsubishi Electric Corp 電気車制御装置
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
CA2610196A1 (en) * 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0607196D0 (en) * 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
JP2009539884A (ja) * 2006-06-12 2009-11-19 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしてのアゼチジン誘導体
EP2032570A4 (en) * 2006-06-13 2010-10-27 Merck Frosst Canada Ltd AZACYCLOPENTATE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
EP2141994A4 (en) * 2007-04-26 2011-05-18 Avalon Pharmaceuticals POLYCYCLIC COMPOUNDS AND USES THEREOF
EP2240482B1 (en) * 2008-01-31 2013-07-17 Sanofi Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
BRPI0906433A2 (pt) * 2008-01-31 2019-09-24 Sanofi Aventis indole-3-carboxamidas cíclicas, sua preparação e seu uso como farmacêutico
HUE034409T2 (en) * 2012-07-16 2018-02-28 Fibrogen Inc Process for the preparation of isoquinoline compounds
US10570146B2 (en) 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
DK3541784T5 (da) 2016-11-18 2024-09-16 Integrative Res Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
TW201823230A (zh) * 2016-12-21 2018-07-01 大陸商江蘇恆瑞醫藥股份有限公司 稠環基氮雜環丁基三唑類衍生物、其製備方法及其在醫藥上的應用
TW201823231A (zh) * 2016-12-28 2018-07-01 大陸商江蘇恆瑞醫藥股份有限公司 氮雜雙環基取代的三唑類衍生物、其製備方法及其在醫藥上的應用
WO2019242642A1 (zh) * 2018-06-20 2019-12-26 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
TW202016092A (zh) * 2018-06-20 2020-05-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｏｔｒ抑制劑的晶型及其製備方法
WO2020001460A1 (zh) * 2018-06-27 2020-01-02 江苏恒瑞医药股份有限公司 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法
CN113582818B (zh) * 2021-08-30 2023-08-01 上海日异生物科技有限公司 一种3-卤-2-烷基苯酚的合成方法
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound
CN114805161B (zh) * 2022-06-14 2023-08-25 南通华祥医药科技有限公司 一种3-氟丫丁啶盐酸盐的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5053411A (en) 1989-04-20 1991-10-01 Anaquest, Inc. N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0904076A1 (en) 1996-04-03 1999-03-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU716381B2 (en) 1996-04-03 2000-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036876A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891356A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2276081A1 (en) 1996-12-30 1998-07-09 Lekhanh O. Tran Inhibitors of farnesyl-protein transferase
BR9813699A (pt) 1997-12-16 2000-10-10 Pfizer Prod Inc Combinação eficaz para o tratamento da impotência
AU763976B2 (en) 1999-07-23 2003-08-07 Shionogi & Co., Ltd. Th2 differentiation inhibitors
CN1195522C (zh) 1999-10-15 2005-04-06 弗·哈夫曼-拉罗切有限公司 苯并二氮杂䓬衍生物
EP1232147B1 (en) 1999-11-15 2008-04-02 Janssen Pharmaceutica N.V. Triazoles as farnesyl transferase inhibitors
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
EP1293503A4 (en) * 2000-05-19 2008-04-02 Astellas Pharma Inc Triazole derivatives
US20030216385A1 (en) 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
MXPA04003170A (es) 2001-10-03 2004-07-08 Pharmacia Corp Compuestos policiclicos, sustituidos, provisto de 5 miembros, utiles para la inhibicion selectiva de la cascada de coagulacion.
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
US7169797B2 (en) 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
BRPI0414663A (pt) 2003-09-22 2006-11-21 Pfizer derivados triazol substituìdos como antagonistas de oxitocina
KR100854872B1 (ko) 2003-12-22 2008-08-28 화이자 인코포레이티드 바소프레신 길항제로서의 트리아졸 유도체
WO2005082866A2 (en) * 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
BRPI0510340A (pt) 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists

Also Published As

Publication number Publication date
NL1030961A1 (nl) 2006-07-21
US20060160786A1 (en) 2006-07-20
EP1841758A1 (en) 2007-10-10
DOP2006000014A (es) 2006-07-31
CA2595569A1 (en) 2006-07-27
NO20074177L (no) 2007-10-16
ES2334517T3 (es) 2010-03-11
MX2007008757A (es) 2008-03-10
US20150322042A1 (en) 2015-11-12
JP4124805B1 (ja) 2008-07-23
EP1841758B1 (en) 2009-11-18
PA8660401A1 (es) 2006-09-08
US9023872B2 (en) 2015-05-05
TNSN07275A1 (fr) 2008-12-31
AP2007004047A0 (en) 2007-06-30
EA200701328A1 (ru) 2007-12-28
GB0501190D0 (en) 2005-03-02
WO2006077496A1 (en) 2006-07-27
PE20060875A1 (es) 2006-09-04
IL184148A0 (en) 2007-10-31
US20170114040A1 (en) 2017-04-27
NL1030961C2 (nl) 2007-01-12
HK1113927A1 (en) 2008-10-17
CA2595569C (en) 2010-07-20
AR055303A1 (es) 2007-08-15
US20130137671A1 (en) 2013-05-30
US9394278B2 (en) 2016-07-19
DE602006010508D1 (de) 2009-12-31
KR20070091023A (ko) 2007-09-06
KR100936854B1 (ko) 2010-01-14
JP2008528476A (ja) 2008-07-31
AU2006207300A1 (en) 2006-07-27
NO338420B1 (no) 2016-08-15
CN101107243A (zh) 2008-01-16
ZA200705718B (en) 2008-08-27
BRPI0606463A2 (pt) 2009-06-30
CN101107243B (zh) 2010-11-24
MA29160B1 (fr) 2008-01-02
US7557131B2 (en) 2009-07-07
CR9219A (es) 2007-07-24
IL184148A (en) 2013-06-27
UY29339A1 (es) 2006-08-31
US20090253674A1 (en) 2009-10-08
US10150752B2 (en) 2018-12-11
DK1841758T3 (da) 2010-01-18
AU2006207300B2 (en) 2011-03-03
US8207198B2 (en) 2012-06-26
ATE449091T1 (de) 2009-12-15
GT200600024A (es) 2006-08-23

Similar Documents

Publication Publication Date Title
TW200637847A (en) Substituted triazole derivatives as oxytocin antagonists
WO2005082866A3 (en) Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
WO2006100588A8 (en) Substituted triazole derivatives as oxytocin antagonists
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TW200626593A (en) Novel compounds
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200745122A (en) New compounds I
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
MX2010012529A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo.
WO2007050587A3 (en) Therapeutic compositions and methods
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
TW200726758A (en) New pyridine analogues
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
GB0513886D0 (en) Novel compounds
HK1115500A1 (en) Isoquinolines as igf-1r inhibitors
TW200738714A (en) New secondary amines
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
TW200628153A (en) Novel compounds
TW200613317A (en) Steroid prodrugs with androgenic action
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.